Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Recursion Pharmaceuticals, Inc. $RXRX

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 3rd quarter, Holdings Channel.com reports. The firm bought 229,617 shares of the company’s stock, valued at approximately $1,121,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its position in Recursion Pharmaceuticals by 20.7% in the second quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company’s stock valued at $39,353,000 after purchasing an additional 1,332,428 shares during the period. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter valued at about $16,040,000. First Trust Advisors LP raised its holdings in shares of Recursion Pharmaceuticals by 82.3% during the 2nd quarter. First Trust Advisors LP now owns 1,880,290 shares of the company’s stock valued at $9,514,000 after buying an additional 848,791 shares during the period. Bank Pictet & Cie Europe AG acquired a new position in Recursion Pharmaceuticals during the 3rd quarter worth approximately $7,954,000. Finally, Vestmark Advisory Solutions Inc. boosted its holdings in Recursion Pharmaceuticals by 89.6% in the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 1,339,139 shares of the company’s stock worth $6,776,000 after acquiring an additional 632,900 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on RXRX. JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $10.00 to $11.00 in a research note on Wednesday, December 17th. UBS Group set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Morgan Stanley set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $9.40.

Recursion Pharmaceuticals Trading Down 3.0%

RXRX opened at $4.19 on Friday. Recursion Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $12.36. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.60 and a quick ratio of 4.60. The stock has a market capitalization of $2.18 billion, a PE ratio of -2.33 and a beta of 0.95. The firm’s fifty day moving average price is $4.50 and its 200 day moving average price is $4.99.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.02. The company had revenue of $5.18 million during the quarter, compared to analyst estimates of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The firm’s revenue for the quarter was down 80.1% compared to the same quarter last year. During the same period last year, the business earned ($0.34) EPS. As a group, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Blake Borgeson sold 220,000 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $4.36, for a total value of $959,200.00. Following the completion of the sale, the director directly owned 6,649,863 shares of the company’s stock, valued at $28,993,402.68. The trade was a 3.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Ben R. Taylor sold 21,383 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $4.18, for a total value of $89,380.94. Following the sale, the chief financial officer owned 761,550 shares in the company, valued at $3,183,279. The trade was a 2.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 585,786 shares of company stock worth $2,558,598. Corporate insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.